Search Within

Matthew J Matasar

  1. "Colette Owens"
  2. "Radiology, Department of"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (3)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Hematologic Malignancies, Division of (13)
  4. Lymphoma (13)
  5. Molecular Imaging and Therapy Service (13)
  6. Radiology, Department of (13)

More Groups

People
  1. Andrew Zelenetz (13)
  2. Anita Kumar (13)
  3. Colette Owens (13)
  4. Heiko Schoder (13)
  5. David Straus (12)
  6. Paul Hamlin (12)

More People

Years
  1. 2023 (2)
  2. 2022 (2)
  3. 2021 (4)
  4. 2020 (2)
  5. 2019 (2)
  6. 2018 (1)
Publications
  1. Blood (8)
  2. Blood Advances (1)
  3. Blood Cancer Journal (1)
  4. British Journal of Haematology (1)
  5. Hematological Oncology (1)
  6. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (9)
  2. American Society of Clinical Oncology (1)
  3. John Wiley & Sons (1)
  4. Nature Publishing Group (1)
  5. Wiley Blackwell (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study
    Meeting Abstract

    Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; more...
    Blood (2020)

    Fulltext@MSK | Save